Cargando…

HOW TO INCORPORATE MRD IN CLINICAL TRIALS

Detalles Bibliográficos
Autor principal:	San-Miguel, Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Main Program
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011760/ http://dx.doi.org/10.1097/01.HS9.0000829512.46921.c8

Ejemplares similares

HOW TO TREAT UNFIT AND FRAIL PATIENTS
por: Cook, Gordon
Publicado: (2022)

HOW TO TREAT HIGH RISK PATIENTS
por: Kaiser, Martin
Publicado: (2022)

THE ATLAS INITIATIVE AND HOW TO IMPROVE ACCESS FOR PATIENTS
por: Morgan, Kate
Publicado: (2022)

HOW TO HARNESS NEW IMMUNOTHERAPIES WITH COMBINATION STRATEGIES?
por: Einsele, H.
Publicado: (2023)

MONOCLONAL GAMMOPATHY OF CLINICAL SIGNIFICANCE
por: Bladé, J.
Publicado: (2023)

FROM BENIGN TO MALIGNANT DISEASE
por: Bolli, Niccolò
Publicado: (2022)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

DRUGGABLE MM THERAPEUTICS: PATHOGENETIC PATHWAYS
por: Ocio, Enrique M
Publicado: (2022)

LIGHT CHAIN DEPOSITION DISEASE
por: Vos, Josephine M.I.
Publicado: (2022)

BONE DISEASE
por: Terpos, Evangelos
Publicado: (2022)

EXTRAMEDULLARY DISEASE
por: Beksac, Meral
Publicado: (2022)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

COVID-19 AND MYELOMA
por: Ludwig, H, et al.
Publicado: (2022)

IMMUNOTHERAPY
por: Einsele, Hermann
Publicado: (2022)

CIRCULATING TUMOR CELLS
por: Paiva, Bruno
Publicado: (2022)

TREATMENT AT RELAPSE: WHAT TO DO FIRST?
por: Mateos, Maria-Victoria
Publicado: (2022)

MASS SPECTROMETRY AS A TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION IN THE BLOOD OF MYELOMA PATIENTS
por: Jacobs, J.F.M.
Publicado: (2023)

AL AMYLOIDOSIS UPFRONT TREATMENT AND CURRENT AND FUTURE STUDIES
por: Kastritis, E.
Publicado: (2023)

EARLY DETECTION AND SCREENING FOR MULTIPLE MYELOMA PRECURSORS
por: Thorsteinsdottir, S.
Publicado: (2023)

BONE DISEASE
por: Terpos, E.
Publicado: (2023)

MGRS: DIAGNOSIS AND TREATMENT
por: Bridoux, F.
Publicado: (2023)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

TREATMENT OF TRIPLE-CLASS REFRACTORY DISEASE: BEYOND IMMUNOTHERAPY
por: Gavriatopoulou, M.
Publicado: (2023)

DEBATE UPFRONT vs DELAYED TRANSPLANT
por: Gay, F.
Publicado: (2023)

Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior
por: Qi, Hongchao, et al.
Publicado: (2022)

Do single‐arm trials have a role in drug development plans incorporating randomised trials?
por: Grayling, Michael J., et al.
Publicado: (2015)

Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
por: Kunz, Cornelia Ursula, et al.
Publicado: (2014)

Modeling the dissemination and uptake of clinical trials results
por: Rosas, Scott R., et al.
Publicado: (2013)

A compassionate imagery intervention for patients with persecutory delusions
por: Forkert, Ava, et al.
Publicado: (2022)

Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)
por: Rosebrock, Laina, et al.
Publicado: (2022)

Cognitive appraisals of dissociation in psychosis: a new brief measure
por: Černis, Emma, et al.
Publicado: (2021)

Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis
por: Evans, Rachel, et al.
Publicado: (2021)

Comfrey root: from tradition to modern clinical trials
por: Staiger, Christiane
Publicado: (2012)

Progress in Rett Syndrome: from discovery to clinical trials
por: Percy, Alan K.
Publicado: (2016)

Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018)

Clinical implications of cardiovascular outcome trials in type 2 diabetes
por: Mellbin, L. G., et al.
Publicado: (2019)

A critical review of graphics for subgroup analyses in clinical trials
por: Ballarini, Nicolás M., et al.
Publicado: (2020)

Optimal composite scores for longitudinal clinical trials under the linear mixed effects model
por: Ard, M. Colin, et al.
Publicado: (2015)

Adopting AI: how familiarity breeds both trust and contempt
por: Horowitz, Michael C., et al.
Publicado: (2023)

Program
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3jkoqe3k51bu8eu6b282ej7ijt